Sebastian Krannich

Sebastian Krannich

Auto-generated profile, based on publicly available information

Sebastian Krannich

Institute for Pharmaceutical Microbiology University of Bonn University Clinic Bonn Meckenheimer Allee 168 53115 Bonn Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
DWDaniel A. Wirtz
Daniel A. Wirtz
KLKevin Christopher Ludwig
Kevin Christopher Ludwig
MAMelina Arts
Melina Arts
CMCarina E. Marx
Carina E. Marx
SKSebastian Krannich
Sebastian Krannich
TSTanja Schneider
Tanja Schneider
Hypeptin is a cyclodepsipeptide antibiotic produced by Lysobacter sp. K5869, isolated from an environmental sample by the iChip technology, dedicated to the cultivation of previously uncultured microorganisms. Hypeptin shares structural features with teixobactin and exhibits potent activity against a broad spectrum of gram‐positive pathogens. Using comprehensive in vivo and in vitro analyses, we show that hypeptin blocks bacterial cell wall biosynthesis by binding to multiple undecaprenyl pyrophosphate‐containing biosynthesis intermediates, forming a stoichiometric 2:1 complex. Resistance to hypeptin did not readily develop in vitro. Analysis of the hypeptin biosynthetic gene cluster (BGC) supported a model for the synthesis of the octapeptide. Within the BGC, two hydroxylases were identified and characterized, responsible for the stereoselective β‐hydroxylation of four building blocks when bound to peptidyl carrier proteins. In vitro hydroxylation assays corroborate the biosynthetic hypothesis and lead to the proposal of a refined structure for hypeptin.

26 March 2021 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
DWDaniel A. Wirtz
Daniel A. Wirtz
KLKevin Christopher Ludwig
Kevin Christopher Ludwig
MAMelina Arts
Melina Arts
CMCarina E. Marx
Carina E. Marx
SKSebastian Krannich
Sebastian Krannich
TSTanja Schneider
Tanja Schneider
Hypeptin is a cyclodepsipeptide antibiotic produced by Lysobacter sp. K5869, isolated from an environmental sample by the iChip technology, dedicated to the cultivation of previously uncultured microorganisms. Hypeptin shares structural features with teixobactin and exhibits potent activity against a broad spectrum of gram‐positive pathogens. Using comprehensive in vivo and in vitro analyses, we show that hypeptin blocks bacterial cell wall biosynthesis by binding to multiple undecaprenyl pyrophosphate‐containing biosynthesis intermediates, forming a stoichiometric 2:1 complex. Resistance to hypeptin did not readily develop in vitro. Analysis of the hypeptin biosynthetic gene cluster (BGC) supported a model for the synthesis of the octapeptide. Within the BGC, two hydroxylases were identified and characterized, responsible for the stereoselective β‐hydroxylation of four building blocks when bound to peptidyl carrier proteins. In vitro hydroxylation assays corroborate the biosynthetic hypothesis and lead to the proposal of a refined structure for hypeptin.